Abstract 617P
Background
Ewing sarcoma is a neoplasm of neuroectodermal origin arising from bone or soft tissue. The annual incidence of Ewing sarcoma in children is 2.93 per 1,000,000. Acute myeloid leukaemia (AML) is one of the most common malignancies as a complication of primary cancer therapy. There are very few studies reported the association of Ewing sarcoma with AML. So, our aim is to quantify the risk of developing AML in Ewing sarcoma patients and provide updated evidence to the literature.
Methods
We extracted the data from the surveillance, Epidemiology and End Results (SEER) statistical analysis software package (SEER*Stat, version 8.4.1.2). We used the MP-SIR session to identify patients who had ewing sarcoma as a first primary tumor, then diagnosed with acute myeloid leukaemia as a second primary malignancy between 2000 and 2020. We assessed the SIR as Observed/Expected(O/E) and Excess Absolute Risk (EAR) per 10,000 with a 95% Confidence Interval (CI) and statistical significance at P<0.05.
Results
A total of 2631 patients had a median follow-up of 120+ months. Patient with Ewing sarcoma had an increased risk to develop AML with O/E of 145.98 (95% CI:101.68 -203.03, P<0.05, EAR= 21.79). The total cohort of patients had a PC of 32.7, APC of 1.3 (95% CI: 0.6 -2.0; P<0.05. Female patients had a PC of 46.5, APC of 1.7 (95% CI: 0.5 -2.9; P<0.05). about 35 patients developed acute non lymphocytic leukaemia (ANLL) with O/E 130.92 (95% [CI] 91.19 -182.08; P<0.05, EAR 21.77).
Conclusions
Ewing sarcoma is a very rare tumor that it is hard to assess the risk of multiple primary malignancies associated with it. In this study we found patients who developed a primary Ewing sarcoma had significantly high risk of developing Acute myeloid leukemia especially in the first year after diagnosis, so we recommend to start screening for AML once Ewing sarcoma is diagnosed for early detection and better management plan.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
73TiP - Global phase III studies evaluating vepdegestrant in estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: VERITAC-2 and VERITAC-3
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract
78P - First-in-human phase I study of TT-00434, an orally available FGFR (1-3) inhibitor in patients with advanced solid tumors
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
79P - Accelerated identification of recurrent neoantigens for the development of off-the-shelf cancer vaccines
Presenter: Le Son Tran
Session: Poster Display
Resources:
Abstract
80P - Safety, preliminary efficacy, and pharmacokinetics of HLX26 plus serplulimab in advanced solid tumours: An open-label, dose-escalation phase I study
Presenter: Yanmin Wu
Session: Poster Display
Resources:
Abstract
81P - A first-in-human, multiple dose and dose escalation phase I study to investigate the safety, tolerability and antitumor activity of SmarT cells plus PD-1 blocking antibodies in patients with far advanced/metastatic solid tumors
Presenter: Qin Liu
Session: Poster Display
Resources:
Abstract
82P - NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies
Presenter: Gloria Chan
Session: Poster Display
Resources:
Abstract
83P - The updated report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors
Presenter: Yinan Shen
Session: Poster Display
Resources:
Abstract
84P - T cell receptor repertoire profiles of tumor -infiltrating lymphocytes improves neoantigen prioritization for personalized cancer immunotherapy
Presenter: Tran Nguyen
Session: Poster Display
Resources:
Abstract
85P - Oligometastatic solid tumors: Disease characteristics and role of local therapies
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
86P - Efficacy and safety of HLX07 monotherapy in advanced cutaneous squamous cell carcinoma: An open-label, multicentre phase II study
Presenter: Changxing Li
Session: Poster Display
Resources:
Abstract